Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NVCR NovoCure Ltd
- Stocks
- Healthcare
- NASDAQ: NVCR
Price (delayed)
$17.6
Market cap
$1.96B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.51
Enterprise value
$2.53B
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating
Highlights
The gross profit has increased by 22% YoY and by 2.5% QoQ
The company's revenue rose by 18% YoY and by 2.7% QoQ
The company's quick ratio has shrunk by 76% YoY
NovoCure's debt has increased by 17% YoY and by 3.2% from the previous quarter
Key stats
What are the main financial stats of NVCR
Market
Valuations
Earnings
Shares outstanding
111.49M
Market cap
$1.96B
Enterprise value
$2.53B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.34
Price to sales (P/S)
3.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.07
Revenue
$621.71M
Gross profit
$479.7M
Operating income
-$166.84M
Net income
-$164.19M
EBIT
-$166.84M
EBITDA
-$155.1M
Free cash flow
-$72.14M
Per share
Balance sheet
Liquidity
EPS
-$1.51
EPS diluted
-$1.51
Free cash flow per share
-$0.65
Book value per share
$3.29
Revenue per share
$5.64
TBVPS
$11.32
Total assets
$1.25B
Total liabilities
$886.85M
Debt
$696.73M
Equity
$361.96M
Working capital
$346M
Debt to equity
1.92
Current ratio
1.47
Quick ratio
1.41
Net debt/EBITDA
-3.66
Margins
Efficiency
Dividend
EBITDA margin
-24.9%
Gross margin
77.2%
Net margin
-26.4%
Operating margin
-26.8%
Return on assets
-13.3%
Return on equity
-45.5%
Return on invested capital
-14.5%
Return on capital employed
-33%
Return on sales
-26.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVCR stock price
How has the NovoCure stock price performed over time
Intraday
-4.66%
1 week
-0.62%
1 month
1.38%
1 year
-0.68%
YTD
-40.94%
QTD
-1.12%
Financial performance
How have NovoCure's revenue and profit performed over time
Revenue
$621.71M
Gross profit
$479.7M
Operating income
-$166.84M
Net income
-$164.19M
Gross margin
77.2%
Net margin
-26.4%
NovoCure's operating margin has increased by 34% YoY and by 5% QoQ
NovoCure's net margin has increased by 28% YoY and by 5% from the previous quarter
NovoCure's operating income has increased by 22% YoY and by 2.1% QoQ
The gross profit has increased by 22% YoY and by 2.5% QoQ
Price vs fundamentals
How does NVCR's price correlate with its fundamentals
Growth
What is NovoCure's growth rate over time
Valuation
What is NovoCure stock price valuation
P/E
N/A
P/B
5.34
P/S
3.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.07
NVCR's EPS is up by 16% year-on-year and by 3.2% since the previous quarter
The price to book (P/B) is 71% lower than the 5-year quarterly average of 18.4 and 11% lower than the last 4 quarters average of 6.0
NVCR's price to sales (P/S) is 78% lower than its 5-year quarterly average of 14.1 and 16% lower than its last 4 quarters average of 3.7
The company's revenue rose by 18% YoY and by 2.7% QoQ
Efficiency
How efficient is NovoCure business performance
NVCR's return on sales is up by 34% year-on-year and by 5% since the previous quarter
The company's return on assets rose by 21% YoY and by 6% QoQ
NovoCure's ROIC has increased by 10% YoY and by 2% from the previous quarter
NovoCure's return on equity has increased by 10% YoY and by 2.8% QoQ
Dividends
What is NVCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVCR.
Financial health
How did NovoCure financials performed over time
NovoCure's total assets is 41% more than its total liabilities
The company's current ratio has shrunk by 77% YoY
The company's quick ratio has shrunk by 76% YoY
NovoCure's debt is 92% more than its equity
NovoCure's debt has increased by 17% YoY and by 3.2% from the previous quarter
NVCR's debt to equity is up by 16% YoY and by 2.1% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.